Aravax’s PVX108 has received FDA Fast Track designation as the next-generation immunotherapy advances through Phase 2 studies for peanut allergy.

Melbourne- and Oxford-based biotechnology company Aravax has received FDA Fast Track designation for PVX108, its lead investigational immunotherapy for the treatment of peanut allergy.

The designation applies as Phase 2 studies of PVX108 continue at clinical sites in the US and Australia, with key data expected later in 2026.

The FDA’s Fast Track programme is intended to support the development and review of medicines for serious or life-threatening conditions where there is an unmet medical need.

For developers, the designation can provide more frequent interactions with the FDA during drug development and may allow companies to seek other expedited pathways if relevant criteria are met.

FDA Fast Track designation supports PVX108 development

Fast Track designation does not mean that a medicine has been approved or that its safety and efficacy have been established. Instead, it is designed to facilitate communication between developers and the FDA during the development process.

Eligible medicines may benefit from more frequent meetings with the regulator to discuss development plans and the collection of appropriate data. The programme can also allow for more frequent written communication with the FDA.

Depending on the data generated during development and whether the relevant criteria are met, Fast Track-designated medicines may also become eligible for Accelerated Approval or Priority Review.

The FDA may also allow Rolling Review, enabling completed sections of a future application to be submitted for review as they become available rather than requiring the full application to be completed before submission.

For Aravax, the designation provides regulatory support as the company progresses PVX108 through clinical development.

Dr Pascal Hickey, CEO of Aravax, said: “There remains a critical need for effective new treatments for food allergy and we believe PVX108 has the potential to offer a safer, more convenient and disease modifying treatment for the millions affected by peanut allergy worldwide.”

PVX108 aims to retrain the immune system

PVX108 is described by Aravax as a next-generation immunotherapy based on proprietary peptides designed to target the immune response to peanut.

The company’s approach is intended to retrain the immune system to tolerate peanut while avoiding treatment-induced acute allergic reactions.

This approach is being investigated as an alternative to existing methods of managing peanut allergy, with the potential to address the need for treatments that can modify the underlying immune response.

However, the safety and efficacy of PVX108 remain under investigation. The ongoing Phase 2 studies will be important in determining whether the treatment can demonstrate the benefits suggested by the company’s development programme.

The Phase 2 studies are taking place in the US and Australia, with Aravax expecting to report key data later in 2026.

Phase 2 data will be the next key milestone

The FDA Fast Track designation comes as Aravax moves towards its next clinical development milestone.

The company said the designation could support more frequent communication with the FDA during the development of PVX108. Such interaction can help developers discuss clinical development plans and regulatory requirements as data emerge.

Hickey said receiving the designation was “a significant step for PVX108’s future development”, adding that more frequent communication with the FDA can support the programme as it progresses.

The forthcoming Phase 2 data will therefore be an important test of the investigational immunotherapy and its potential role in peanut allergy treatment.

For now, PVX108 remains an investigational therapy and has not been approved for the treatment of peanut allergy. The programme’s progress will depend on the clinical data generated in its ongoing studies and subsequent regulatory review.